WO2014133567A1 - Methods of producing enriched populations of tumor-reactive t cells from tumor - Google Patents
Methods of producing enriched populations of tumor-reactive t cells from tumor Download PDFInfo
- Publication number
- WO2014133567A1 WO2014133567A1 PCT/US2013/038799 US2013038799W WO2014133567A1 WO 2014133567 A1 WO2014133567 A1 WO 2014133567A1 US 2013038799 W US2013038799 W US 2013038799W WO 2014133567 A1 WO2014133567 A1 WO 2014133567A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- tim
- tumor
- lag
- cell population
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 229
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 209
- 238000000034 method Methods 0.000 title claims abstract description 106
- 210000004027 cell Anatomy 0.000 claims abstract description 353
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 100
- 241000124008 Mammalia Species 0.000 claims abstract description 33
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims abstract description 30
- 102000017578 LAG3 Human genes 0.000 claims abstract description 28
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims abstract description 28
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims abstract description 14
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims abstract 27
- 101150030213 Lag3 gene Proteins 0.000 claims abstract 24
- 201000011510 cancer Diseases 0.000 claims description 49
- 210000004881 tumor cell Anatomy 0.000 claims description 37
- 239000000427 antigen Substances 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 239000003937 drug carrier Substances 0.000 claims description 10
- 102000015696 Interleukins Human genes 0.000 claims description 9
- 108010063738 Interleukins Proteins 0.000 claims description 9
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 108010065805 Interleukin-12 Proteins 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 7
- -1 4- IBB Proteins 0.000 claims description 6
- 229940126638 Akt inhibitor Drugs 0.000 claims description 6
- 108090000172 Interleukin-15 Proteins 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 6
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 6
- 239000003197 protein kinase B inhibitor Substances 0.000 claims description 6
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000002463 transducing effect Effects 0.000 claims description 3
- 101100439027 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cdc2 gene Proteins 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 abstract 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 107
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 98
- 230000014509 gene expression Effects 0.000 description 45
- 201000001441 melanoma Diseases 0.000 description 29
- 238000000338 in vitro Methods 0.000 description 20
- 230000009257 reactivity Effects 0.000 description 16
- 102100037850 Interferon gamma Human genes 0.000 description 14
- 108010074328 Interferon-gamma Proteins 0.000 description 14
- 239000012636 effector Substances 0.000 description 13
- 230000000735 allogeneic effect Effects 0.000 description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
- 230000028327 secretion Effects 0.000 description 11
- 230000003827 upregulation Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 238000003501 co-culture Methods 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000004186 co-expression Effects 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 239000010432 diamond Substances 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 3
- 238000011467 adoptive cell therapy Methods 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 238000011469 lymphodepleting chemotherapy Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150059217 CDK12 gene Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100026371 MHC class II transactivator Human genes 0.000 description 1
- 108700002010 MHC class II transactivator Proteins 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 201000007696 anal canal cancer Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 201000003956 middle ear cancer Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000007425 nasal cavity carcinoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/51—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
Definitions
- Adoptive cell therapy (ACT) using tumor-reactive T cells can produce positive clinical responses in some cancer patients. Nevertheless, several obstacles to the successful use of ACT for the treatment of cancer and other diseases remain. For example, T cells isolated from a tumor may not exhibit sufficient tumor-specific reactivity. Accordingly, there is a need for improved methods of obtaining a population of tumor-reactive T cells from tumors.
- An embodiment of the invention provides a method of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4-lBB, and PD-1 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor- reactive T cells.
- Another embodiment of the invention provides a method of administering a cell population enriched for tumor-reactive T cells to a mammal, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4-lBB, and PD-1 from the bulk population; (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells; and (d) administering the cell population enriched for tumor-reactive T cells to the mammal.
- Still another embodiment of the invention provides a method of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4- IBB, and PD-1 from the bulk population; (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells; and (d) combining the cell population enriched for tumor-reactive T cells with a pharmaceutically acceptable carrier to obtain a pharmaceutical composition comprising a cell population enriched for tumor- reactive T cells.
- Another embodiment of the invention provides a cell population enriched for tumor-reactive T cells obtained by a method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4- IBB, and PD-1 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor- reactive T cells for use in administering the cell population enriched for tumor-reactive T cells to a mammal.
- Additional embodiments of the invention provide related populations of cells and methods of treating or preventing cancer.
- Figure 1A is a graph showing the percentage of CD3 + /CD8 + cells isolated from fresh melanoma tumor samples expressing PD-1, TIM-3, LAG-3, 4-1BB, OX40, CD25, CD28, CD27, or CD70. Each dot represents one tumor.
- Figure 1 B is a graph showing fold-expansion of the numbers of CD8 + cells that were isolated from a fresh melanoma tumor sample (FrTu#1913), sorted for expression of CD8, PD-1, LAG-3, TIM-3, or 4-1BB, or lack of expression of PD-1 , LAG-3, TIM-3, or 4- 1BB, after in vitro expansion (REP) for 14 days.
- FIGS 2A-2E show interferon (IFN)-gamma secretion (pg/ml) (black bars) or percentage of effector T-cells (T eff ) expressing CD3, CD8, and 4-1 BB (grey bars) by CD8 + cells isolated from one of five different melanoma tumor samples (FrTu#1913 (A),
- Figures 3A-3C show percent specific lysis of target tumor cell lines TC1913 (autologous) (A), TC3289 (allogeneic) (B), or TC2448 (HLA-A0201 matched) (C) by effector CD8 + T cells that were isolated from melanoma tumor sample FrTu#1913 and sorted for expression of CD8 (open circles), PD-1 (black circles), TIM-3 (black diamonds), LAG-3 (black triangles), or 4- I BB (black squares) or lack of expression of PD-1 (grey circles), TIM- 3 (grey diamonds), LAG-3 (grey triangles), or 4- IBB (grey squares) at the effector:target ratios indicated.
- Figures 3D-3F show percent specific lysis of target tumor cell lines TC3713 (autologous) (D), TC3550 (allogeneic) (E) or TC1379 (allogeneic) (F) by effector CD8 + T cells that were isolated from melanoma tumor sample FrTu#3713 (D-F) and sorted for expression of CD8 (open circles), PD-1 (black circles), TIM-3 (black diamonds), or 4- IBB (black squares) or lack of expression of PD-1 (grey circles), TIM-3 (grey diamonds), or 4- 1BB (grey squares) at the effector :target ratios indicated.
- Figure 4A shows autologous tumor recognition of cells isolated from a melanoma tumor (FrTu#3713), sorted for CD8 + , PD-1 + PD-1 " , 4-lBB + , 4-1BB " , 4-lBB + /PD-l ' , 4- 1BB + /PD-1 + , 4-lBB7PD-l + , or 4-1BB7PD-1 " and expanded in vitro for 14 days. Percentage of CD3 + CD8 + cells expressing 4- IBB upon co-culture with autologous tumor cell lines is shown.
- Figure 4B is a graph showing the percentage of CD3 + CD8 + cells that express 4- 1BB (grey bars) or secrete IFN-gamma (black bars) after being isolated from a melanoma tumor (FrTu#3612).
- Cells were sorted for CD8 + , PD-1 + , PD-1 " , 4-lBB + /PD-l " , 4-1 BB7PD- 1 + , 4-lBB7PD-l + , or 4- 1 BB7PD-1 " populations, expanded in vitro for 14 days and IFN- gamma secretion and 4- IBB up-regulation upon co-culture with autologous tumor cell lines is shown.
- Figures 5A-5C show percent specific lysis of target tumor cell lines TC3713 (autologous) (A), TC3550 (allogeneic) (B) and TCI 379 (allogeneic) (C) by effector CD8 + cells that were isolated from a melanoma tumor (FrTu#3713) and sorted for 4-lBB + /PD-l " (circles)), 4-lBB + /PD-l + (squares), 4-lBB7PD-l + (diamonds), or 4-lBB7PD-l " (*) populations at the effector to target ratios indicated as measured by 51 Cr release assay.
- Figure 6 is a graph showing the percentage of CD8 + cells that express 4-1BB (grey bars) or secrete IFN-gamma (black bars) that were isolated from a gastrointestinal tumor (FrTu#3446b), sorted for CD8 + , PD-1 + , PD-1 " , TIM-3 + , TIM-3 " , 4-lBB + , or 4-1BB " populations and expanded for 21 days in culture. IFN-gamma and 4- IBB up-regulation upon co-culture with autologous tumor cell lines is shown.
- Figures 7 A and 7B are graphs showing the frequency (%) of unique TCR beta chain CDR3 region amino acid sequences of sorted PD- ⁇ cells (2985 TCR clonotypes) (A) or sorted PD-1 + cells (805 TCR clonotypes) (B) after 14 days of in vitro expansion.
- Figure 7C is a graph showing the frequency (%) of unique TCR beta chain CDR3 region amino acid sequences of sorted PD- ⁇ cells (black circles) or sorted PD-1 + cells (grey circles).
- Figure 8 is a graph showing the frequency (%) of TCR ⁇ chain clonotypes in the PD- ⁇ population or in the PD-1 + population that recognize mutated epitopes
- pl4ARF/pl6I K4a black circles
- HLA-A1 lmut grey circles
- open circles open circles
- CD8 + cells that also express any one or more of TIM-3 T Cell Ig- and mucin-domain-containing molecule-3
- LAG-3 lymphocyte activation gene 3; CD223)
- 4-1 BB CD137
- PD-1 CD279
- an embodiment of the invention provides a method of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4-1BB, and PD-1 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells.
- the inventive methods advantageously make it possible to shorten the time of in vitro culture of cells prior to administering the cells to a patient.
- the inventive methods advantageously may provide a cell population enriched for tumor-reactive T cells that may be administered to a patient without having to screen for autologous tumor recognition.
- the method may comprise obtaining a bulk population of T cells from a tumor sample by any suitable method known in the art.
- a bulk population of T cells can be obtained from a tumor sample by dissociating the tumor sample into a cell suspension from which specific cell populations can be selected.
- Suitable methods of obtaining a bulk population of T cells may include, but are not limited to, any one or more of mechanically dissociating (e.g., mincing) the tumor, enzymatically dissociating (e.g., digesting) the tumor, and aspiration (e.g., as with a needle).
- the bulk population of T cells obtained from a tumor sample may comprise any suitable type of T cell.
- the bulk population of T cells obtained from a tumor sample comprises tumor infiltrating lymphocytes (TILs).
- the tumor sample may be obtained from any mammal.
- mammal refers to any mammal including, but not limited to, mammals of the order Logomorpha, such as rabbits; the order Carnivora, including Felines (cats) and Canines (dogs); the order Artiodactyla, including Bovines (cows) and Swines (pigs); or of the order Perssodactyla, including Equines (horses). It is preferred that the mammals are non-human primates, e.g., of the order Primates, Ceboids, or Simoids
- the mammal may be a mammal of the order Rodentia, such as mice and hamsters.
- the mammal is a non-human primate or a human.
- An especially preferred mammal is the human.
- the method may comprise specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4-1BB, and PD-1 from the bulk population.
- the method comprises selecting cells that also express CD3.
- the method may comprise specifically selecting the cells in any suitable manner.
- the selecting is carried out using flow cytometry.
- the flow cytometry may be carried out using any suitable method known in the art.
- the flow cytometry may employ any suitable antibodies and stains.
- the specific selection of CD3, CD8, TIM-3, LAG-3, 4-1BB, or PD-1 may be carried out using anti-CD3, anti-CD8, anti-TIM-3, anti-LAG-3, anti-4-lBB, or anti-PD-1 antibodies, respectively.
- the antibody is chosen such that it specifically recognizes and binds to the particular biomarker being selected.
- the antibody or antibodies may be conjugated to a bead (e.g., a magnetic bead) or to a fluorochrome.
- the flow cytometry is fluorescence-activated cell sorting (FACS).
- specifically selecting may comprise specifically selecting CD8 + T cells that are positive for expression of any one of TIM-3, LAG-3, 4-1 BB, or PD-1, any combination of two or three of TIM-3, LAG-3, 4-1 BB, and PD- 1 or all four of TIM-3, LAG-3, 4-1BB, and PD-1.
- specifically selecting may comprise specifically selecting T cells that are single positive for expression of any one of TIM-3, LAG-3, 4- IBB, and PD-1 or specifically selecting T cells that are double, triple, or quadruple positive for simultaneous co-expression of any two, three or four of TIM-3, LAG- 3, 4- IBB, and PD-1.
- the method comprises specifically selecting CD8 + T cells that express TIM-3 from the bulk population. In another embodiment, the method comprises specifically selecting CD8 + T cells that express LAG-3 from the bulk population. In still another embodiment, the method comprises specifically selecting CD8 + T cells that express 4- IBB from the bulk population. In still another embodiment of the invention, the method comprises specifically selecting CD8 + T cells that express PD-1 from the bulk population.
- An additional embodiment of the invention provides a method comprising specifically selecting CD8 + T cells that are (i) 4-lBB + /PD-l + , (ii) 4-lBB7PD-l + , and/or (iii) 4-lBB + /PD-l " from the bulk population.
- Still another embodiment of the invention provides a method comprising specifically selecting CD8 + T cells that are (i) TIM-3 + /LAG-3 + , (ii) TIM-37LAG-3 + , or (iii) TIM-3 + /LAG-3 " from the bulk population.
- Another embodiment of the invention provides a method comprising specifically selecting CD8 + T cells that are (i) 4-lBB + /LAG-3 + , (ii) 4- lBB7LAG-3 + , or (iii) 4-lBB + /LAG-3 " from the bulk population.
- Still another embodiment of the invention provides a method comprising specifically selecting CD8 + T cells that are (i) 4- lBB + /TIM-3 + , (ii) 4-lBB7TIM-3 + , or (iii) 4-lBB + /TIM-3- from the bulk population.
- any of the methods described herein may further comprise selecting cells that also express CD3 + .
- specifically selecting may comprise specifically selecting combinations of CD8 + cells expressing any of the markers described herein.
- the method may produce a cell population that is enriched for tumor- reactive cells that comprises a mixture of cells expressing any two, three, four, or more of the biomarkers described herein.
- specifically selecting comprises specifically selecting any of the following combinations of cells: (a) PD-1 + cells and 4-lBB + cells, (b) PD-1 + cells and LAG-3 + cells, (c) PD-1 + cells and TIM-3 + cells, (d) 4- 1BB + cells and LAG-3 + cells, (e) 4-lBB + cells and TIM-3 + cells, (f) LAG-3 + cells and TIM- 3 + cells, (g) PD- cells, 4-lBB + cells, and LAG-3 + cells, (h) PD-1 + cells, 4-lBB + cells, and TIM-3 + cells, (i) PD-1 + cells, LAG-3 + cells, and TIM-3 + cells, (j) 4-lBB + cells, LAG-3 + cells, and TIM-3 + cells, and/or (k) PD-1 + cells, 4-lBB + cells, LAG-3 + cells, and TIM-3 + cells.
- any of the methods described herein may further comprise selecting cells that also express CD8 + and
- the method may comprise separating the selected cells from unselected cells to obtain a cell population enriched for tumor-reactive T cells.
- the selected cells may be physically separated from the unselected cells.
- the selected cells may be separated from unselected cells by any suitable method such as, for example, sorting. Separating the selected cells from the unselected cells preferably produces a cell population that is enriched for tumor-reactive T cells.
- the cell populations obtained by the inventive methods are advantageously enriched for tumor-reactive T cells.
- the cell populations obtained by the inventive methods may comprise a higher proportion of tumor reactive T cells as compared to cell populations that have not been obtained by sorting for expression of any one or more of TIM-3, LAG-3, 4-1 BB, and PD-1.
- the method comprises obtaining the cell population enriched for tumor-reactive T cells without screening for autologous tumor recognition.
- inventive methods advantageously provide a cell population that is enriched for cells that have tumor reactivity without having to screen the cells for autologous tumor recognition.
- the method does not comprise non-specifically stimulating the bulk population of T cells prior to specifically selecting the cells.
- the inventive methods advantageously provide a cell population that is enriched for tumor reactive T cells without stimulating the bulk population of T cells nonspecifically (e.g., with anti-4-lBB antibodies, anti-CD3 antibodies, anti-CD28 antibodies).
- the method further comprises expanding the numbers of T cells in the enriched cell population obtained by the inventive methods in vitro.
- the numbers of T cells may be increased at least about 3-fold (or 4-, 5-, 6-, 7-, 8-, or 9-fold), more preferably at least about 10-fold (or 20-, 30-, 40-, 50-, 60-, 70-, 80-, or 90-fold), more preferably at least about 100-fold, more preferably at least about 1 ,000 fold, or most preferably at least about 100,000-fold.
- the numbers of T cells may be expanded using any suitable method known in the art. Exemplary methods of expanding the numbers of cells are described in U.S. Patent 8,034,334 and U.S. Patent Application Publication No.
- the method further comprises culturing the enriched cell population obtained by the inventive methods in the presence of any one or more of TWS119, interleukin (IL)-21 , IL-12, IL-15, IL-7, transforming growth factor (TGF) beta, and AKT inhibitor (AKTi).
- TWS119 interleukin
- IL-12 interleukin-12
- IL-15 transforming growth factor
- IL-7 transforming growth factor beta
- AKT inhibitor AKT inhibitor
- the method further comprises transducing or transfecting the cells of the enriched population obtained by any of the inventive methods described herein with a nucleotide sequence encoding any one or more of IL-12, IL-7, IL-15, IL-2, IL-21, mirl55, and anti-PD-1 siRNA.
- the method further comprises stimulating the enriched cell population obtained by the inventive methods with a cancer antigen and/or with autologous tumor cells.
- Stimulating the enriched cell population with a cancer antigen and/or with autologous tumor cells may be carried out by any suitable method.
- stimulating the enriched cell population may be carried out by physically contacting the enriched cell population with a cancer antigen and/or with autologous tumor cells.
- stimulating the enriched cell population with a cancer antigen and/or with autologous tumor cells may, advantageously, enhance the anti-tumor reactivity of the enriched cell population.
- cancer antigen refers to any molecule (e.g., protein, peptide, lipid, carbohydrate, etc.) solely or predominantly expressed or over-expressed by a tumor cell or cancer cell, such that the antigen is associated with the tumor or cancer.
- the cancer antigen can additionally be expressed by normal, non-tumor, or non-cancerous cells.
- normal, non-tumor, or noncancerous cells are normally expressed by normal, non-tumor, or noncancerous cells.
- the tumor or cancer cells can over-express the antigen or express the antigen at a significantly higher level, as compared to the expression of the antigen by normal, non-tumor, or noncancerous cells.
- the cancer antigen can additionally be expressed by cells of a different state of development or maturation.
- the cancer antigen can be additionally expressed by cells of the embryonic or fetal stage, which cells are not normally found in an adult host.
- the cancer antigen can be additionally expressed by stem cells or precursor cells, which cells are not normally found in an adult host.
- the cancer antigen can be an antigen expressed by any cell of any cancer or tumor, including the cancers and tumors described herein.
- the cancer antigen may be a cancer antigen of only one type of cancer or tumor, such that the cancer antigen is associated with or characteristic of only one type of cancer or tumor.
- the cancer antigen may be a cancer antigen (e.g., may be characteristic) of more than one type of cancer or tumor.
- the cancer antigen may be expressed by both breast and prostate cancer cells and not expressed at all by normal, non-tumor, or non-cancer cells.
- Exemplary cancer antigens may include any one or more of gplOO, MART-1, MAGE-A1 , MAGE-A2, MAGE- A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE- A 10, MAGE-A1 1 , MAGE-A12, NY-ESO-1, vascular endothelial growth factor receptor-2
- VEGFR-2 epidermal growth factor receptor variant III
- HER-2 epidermal growth factor receptor variant III
- EGFR III epidermal growth factor receptor variant III
- the inventive methods advantageously produce cell populations enriched for tumor-reactive T cells.
- the T cells may be tumor-reactive such that they specifically recognize, lyse, and/or kill tumor cells.
- an embodiment of the invention provides an isolated or purified cell population enriched for tumor-reactive T cells obtained by any of the inventive methods described herein.
- the isolated or purified cell population comprises any one or more of (a) CD874-1BB + /PD-1 + T cells, (b) CD874- I BBVPD- T cells, (c) CD8 + /4-lBB7PD-l " T cells, (d) CD8 + /LAG-3 + /PD-l + T cells, (e) CD87LAG-37PD-1 + T cells, (f) CD87LAG-37PD-1 " T cells, (g) CD87TIM-37PD-1 + T cells, (h) CD8 + /TIM-37PD-1 + T cells, (i) CD87TIM-37PD-r T cells, (j) CD87TIM-37LAG- 3 + T cells, (k) CD87TIM-37LAG-3 + T cells, (1) CD87TIM-37LAG-3 " T cells, (m) CD8 4- lBB7LAG-3 + T cells, (n) CD874-lBB7LAG-3 + T cells, (o) CD874-1BB7LAG-3
- the isolated or purified cell population comprises (a) CD874-1BB7PD-1 + T cells, (b) CD874- 1 BB7PD-1 + T cells, (c) CD8 4- 1 BB + /PD-1 " T cells, (d) CD87LAG-37PD-1 + T cells, (e) CD87LAG-37PD-1 + T cells, (f) CD87LAG-37PD- 1 " T cells, (g) CD87TIM-37PD-1 + T cells, (h) CD87TIM-37PD-1 + T cells, (i) CD87TIM-37PD- ⁇ T cells, (j) CD87TIM-37LAG-3 + T cells, (k) CD87TIM-37LAG-3 + T cells, (1) CD87TIM- 37LAG-3 " T cells, (m) CD874-1BB7LAG-3 + T cells, (n) CD874-lBB7LAG-3 + T cells, (o) CD8 + /4-lBB + /LAG-3 " T cells, (p) CD87TIM- 37LAG
- the isolated or purified cell population comprises a mixture of cells expressing any of the biomarkers described herein.
- the isolated or purified cell population may comprise a combination of (a) PD-1 + cells and 4-lBB + cells, (b) PD-1 + cells and LAG-3 + cells, (c) PD-1 + cells and TIM-3 + cells, (d) 4-lBB + cells and LAG-3 + cells, (e) 4-lBB + cells and TIM-3 + cells, (f) LAG-3 + cells and TIM-3 + cells, (g) PD-1 + cells, 4-lBB + cells, and LAG-3 + cells, (h) PD-1 + cells, 4-lBB + cells, and TIM-3 + cells, (i) PD-1 + cells, LAG-3 + cells, and TIM-3 + cells, (j) 4-lBB + cells, LAG-3 + cells, and TIM-3 + cells, and/or (k) PD-1 + cells, 4-lBB + cells, LAG-3 + cells, and
- isolated means having been removed from its natural environment.
- purified means having been increased in purity, wherein “purity” is a relative term, and not to be necessarily construed as absolute purity.
- the purity can be at least about 50%, can be greater than 60%, 70% or 80%, 90% or can be 100%.
- Another embodiment of the invention provides a method of administering a cell population enriched for tumor-reactive T cells to a mammal, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4-lBB, and PD-1 from the bulk population; (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells; and (d) administering the cell population enriched for tumor-reactive T cells to the mammal.
- Obtaining a bulk population of T cells from a tumor sample, specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4- IBB, and PD-1 from the bulk population, and separating the selected cells from unselected cells to obtain a cell population may be carried out as described herein with respect to other aspects of the invention.
- the method may further comprise administering the cell population enriched for tumor-reactive T cells to the mammal.
- the cell population enriched for tumor-reactive T cells may be administered in any suitable manner.
- the cell population enriched for tumor-reactive T cells is administered by injection, e.g., intravenously.
- the inventive cell population enriched for tumor-reactive T cells can be included in a composition, such as a pharmaceutical composition.
- the invention provides a pharmaceutical composition comprising any of the cell populations described herein and a pharmaceutically acceptable carrier.
- Another embodiment of the invention provides a method of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4- IBB, and PD-1 from the bulk population; (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells; and (d) combining the cell population enriched for tumor-reactive T cells with a pharmaceutically acceptable carrier to obtain a pharmaceutical composition comprising a cell population enriched for tumor- reactive T cells.
- Obtaining a bulk population of T cells from a tumor sample, specifically selecting CD8 + T cells that express any one or more of TIM-3, LAG-3, 4- IBB, and PD-1 from the bulk population, and separating the selected cells from unselected cells to obtain a cell population may be carried out as described herein with respect to other aspects of the invention.
- the method may comprise combining the cell population enriched for tumor- reactive T cells with a pharmaceutically acceptable carrier to obtain a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells.
- a pharmaceutically acceptable carrier is a pharmaceutically acceptable carrier.
- the carrier can be any of those conventionally used for the administration of cells.
- Such pharmaceutically acceptable carriers are well-known to those skilled in the art and are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one which has no detrimental side effects or toxicity under the conditions of use.
- a suitable pharmaceutically acceptable carrier for the cells for injection may include any isotonic carrier such as, for example, normal saline (about 0.90% w/v of NaCl in water, about 300 mOsm/L NaCl in water, or about 9.0 g NaCl per liter of water), NORMOSOL R electrolyte solution (Abbott, Chicago, IL), PLASMA-LYTE A (Baxter, Deerfield, IL), about 5% dextrose in water, or Ringer's lactate.
- the pharmaceutically acceptable carrier is supplemented with human serum albumen.
- the dose e.g., number of cells in the inventive cell population enriched for tumor-reactive T cells
- administered should be sufficient to effect, e.g., a therapeutic or prophylactic response, in the mammal over a reasonable time frame.
- the number of cells should be sufficient to bind to a cancer antigen, or detect, treat or prevent cancer in a period of from about 2 hours or longer, e.g., 12 to 24 or more hours, from the time of administration. In certain embodiments, the time period could be even longer.
- the number of cells will be determined by, e.g., the efficacy of the particular cells and the condition of the mammal (e.g., human), as well as the body weight of the mammal (e.g., human) to be treated.
- an assay which comprises comparing the extent to which target cells are lysed or one or more cytokines such as, e.g., IFN- ⁇ and IL-2 are secreted upon administration of a given number of such cells to a mammal among a set of mammals of which is each given a different number of the cells, could be used to determine a starting number to be administered to a mammal.
- cytokines such as, e.g., IFN- ⁇ and IL-2
- cytokines such as, e.g., IFN- ⁇ and IL-2 are secreted, upon administration of a certain number of cells, can be assayed by methods known in the art.
- Secretion of cytokines such as, e.g., IL-2 may also provide an indication of the quality (e.g., phenotype and/or effectiveness) of a cell preparation.
- the number of the cells from the inventive cell population enriched for tumor- reactive T cells also will be determined by the existence, nature and extent of any adverse side effects that might accompany the administration of a particular cell population.
- the attending physician will decide the number of the cells with which to treat each individual patient, taking into consideration a variety of factors, such as age, body weight, general health, diet, sex, route of administration, and the severity of the condition being treated.
- the number of cells can be aboutlO x 10 6 to about 10 x 10 u cells per infusion, about 10 x 10 9 cells to about 10 x 10 n cells per infusion, or 10 x 10 7 to about 10 x 10 9 cells per infusion.
- the cell populations obtained by the inventive methods may, advantageously, make it possible to effectively treat or prevent cancer.
- the cell populations obtained by the inventive methods can be used in methods of treating or preventing cancer.
- the invention provides a method of treating or preventing cancer in a mammal, comprising administering to the mammal the pharmaceutical compositions or cell populations obtained by any of the inventive methods described herein in an amount effective to treat or prevent cancer in the mammal.
- Another embodiment of the invention provides a method of treating or preventing cancer in a mammal, comprising administering a cell population enriched for tumor-reactive T cells to a mammal by any of the inventive methods described herein in an amount effective to treat or prevent cancer in the mammal.
- inventive methods can provide any amount or any level of treatment or prevention of cancer in a mammal.
- the treatment or prevention provided by the inventive method can include treatment or prevention of one or more conditions or symptoms of the disease, e.g., cancer, being treated or prevented.
- prevention can encompass delaying the onset of the disease, or a symptom or condition thereof.
- the cells can be cells that are allogeneic or autologous to the mammal.
- the cells are autologous to the mammal.
- An embodiment of the invention further comprises lymphodepleting the mammal prior to administering any of the enriched cell populations obtained by any of the inventive methods described herein.
- lymphodepletion include, but may not be limited to, nonmyeloablative lymphodepleting chemotherapy, myeloablative lymphodepleting chemotherapy, total body irradiation, etc.
- the cancer can be any cancer, including any of sarcomas (e.g., synovial sarcoma, osteogenic sarcoma, leiomyosarcoma uteri, and alveolar rhabdomyosarcoma), lymphomas (e.g., Hodgkin lymphoma and non-Hodgkin lymphoma), hepatocellular carcinoma, glioma, head-neck cancer, acute lymphocytic cancer, acute myeloid leukemia, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer (e.g., colon carcinoma
- sarcomas e
- This example demonstrates the frequency of CD3 + /CD8 + cells in a fresh melanoma tumor digest sample expressing PD-1 , TIM-3, LAG-3 or 4- IBB.
- This example also demonstrates that co-expression of 1) TIM-3 and PD-1, 2) LAG-3 and PD-1 , and 3) LAG-3 and TIM-3 by CD8 + T cells isolated from a fresh melanoma tumor sample.
- This example also demonstrates the expression of PD- 1 , TIM-3, or LAG-3 by MART-l 27-35 reactive cells.
- This example demonstrates a method of specifically selecting CD3 + CD8 + cells that also express one of PD-1, TIM-3, LAG-3 and 4- IBB and expanding the numbers of the selected cells.
- the numbers of cells were then expanded using a rapid expansion protocol (200-fold excess irradiated feeders, 30 ng/ml anti-CD3 and 500 CU/ml IL-2) and fold-expansion of the isolated populations was measured. The results are shown in Figure IB. As shown in Figure IB, the numbers of CD8 + cells that also express one of PD-1, TIM-3, LAG-3 and 4- IBB were expanded.
- This example demonstrates the in vitro reactivity of T cells isolated from a fresh melanoma tumor sample and sorted for expression of CD8 and one of PD-1 , LAG-3, TIM-3, and 4- IBB.
- 4- IBB up-regulation is an indicator of TCR stimulation. It has been observed that after the numbers of T cells are expanded and in the absence of TCR stimulation, 4- IBB expression is lost. It has also been observed that after the numbers of cells are expanded and the cells are co-cultured with an autologous tumor cell line, T cells that had previously lost 4- 1BB expression and which are stimulated by the tumor cell line will re-express 4- IBB.
- 4- IBB expression is measured 24 hours after co-culture with autologous tumor as a marker of TCR stimulation against the autologous tumor cell line.
- a single cell suspension from a fresh melanoma tumor digest sample (FrTu#1913) was rested overnight without cytokines and sorted for the following populations: CD8 + , CD8 + /PD-1 + , CD87LAG3 + , CD8 + /TIM-3 + , CD8 + /4-lBB + , CD8 + /PD-1 " , CD8 + /LAG3 " , CD87TIM-3 " , or CD874-1BB " populations by FACS as described in Example 3.
- the numbers of sorted cells were expanded in vitro for 14 days. On day 14, the cells were washed and co-cultured against an autologous tumor cell line (1 x 10 5 effectors: ! x 10 5 target cells).
- Reactivity was assessed by quantifying IFN-gamma release and the percentage of CD8 + cells expressing 4- IBB 24 hours after co-culture with an autologous tumor cell line (TCI 913) and allogeneic (Alio.) tumor cell lines.
- TCI 913 autologous tumor cell line
- Alio. allogeneic tumor cell lines.
- the percentage of CD8 + cells recognizing a specific mutated epitope (CD n2A) targeted by T cells was also quantified using a tetramer against this particular epitope. The results are shown in Tables 1 and 2 and in Figures 2A-2E.
- T cells isolated from a fresh melanoma tumor sample and sorted for expression of CD8 and one of PD-1, LAG-3, TIM-3, and 4- IBB have reactivity against autologous tumor cell lines as measured by IFN-gamma secretion, 4- IBB expression, and percentage of cells recognizing CDKn2A.
- T cells isolated from each of five different fresh melanoma tumor samples and sorted for expression of CD8 and one of PD-1, LAG-3, TIM-3, and 4- IBB have reactivity against autologous tumor cell lines as measured by IFN-gamma secretion and 4- IBB expression.
- This example demonstrates the reactivity of CD8 + cells isolated from a melanoma tumor sample and sorted for expression of 4- IBB and/or PD-1.
- Cells were isolated from fresh melanoma tumor samples from 3 patients and were sorted for CD3 + /CD8 + /4-lBB + /PD-l ' , CD3 + /CD8 + /4-lBB + /PD-l + , CD3 + /CD8 + /4-lBB7PD- 1 + , CD3 + /CD8 + /4-lBB7PD-r, CD3 + /CD8 + /PD-1 + , CD3 + /CD8 + /4-lBB + , CD3 + /CD8 + /PD-1 ⁇ or CD3 + /CD8 + /4-lBB " populations by FACS.
- Sorted cells were co-cultured with autologous tumor cells, and up-regulation of 4- IBB expression was measured by flow cytometry. For all three tumor samples, the results showed that T cells recognizing autologous tumor (as measured by up-regulation of 4- IBB expression) can be found in single positive PD-1 + or 4- 1BB + expressing cells, but the highest frequency of tumor-reactive cells (as measured by 4- 1BB up-regulation) was found in the population co-expressing both 4- IBB and PD-1 in the fresh melanoma tumor digest sample.
- a single cell suspension from melanoma tumor FrTu#3612 was rested overnight without cytokines and the cells were sorted for CD8 + , CD87PD-1 + , CD8 + PD-1 ⁇ CD874-1BB7PD-1 " , CD874- 1 BB7PD- 1 + , CD874- 1 BB7PD- 1 + , and CD8 + /4- 1 BB7PD- 1 ' populations by FACS. The numbers of sorted cells were expanded for 14 days in vitro.
- the cells were washed and co-cultured against the autologous tumor cell line (1 x 10 5 effectors: 1 x 10 5 target cells) and reactivity was assessed by quantifying the percentage of CD8 + cells expressing 4-1BB (FrTu#3612 and FrTu#3713) and/or the amount of IFN-gamma secretion (FrTu#3612) 24 hours after co-culture.
- the results are shown in Figures 4A and 4B.
- the cells sorted for double-positive PD-1 and 4- IBB co-expression displayed similar levels of 4- IBB up-regulation as that demonstrated by cells sorted based on single positive PD-1 or 4-1BB expression.
- the cells sorted for double-positive PD-1 and 4- IBB co-expression displayed similar levels of 4- IBB up- regulation and IFN-gamma secretion as that demonstrated by cells sorted based on single positive PD-1 expression.
- GI gastrointestinal
- a single cell suspension from a fresh gastrointestinal (GI) tract tumor sample (FrTu#3446b) was rested overnight without cytokines and sorted according to expression of PD-1 , TIM-3, or 4- IBB by FACS.
- the numbers of sorted cells were expanded in vitro for 14 days. On day 14, cells were washed and co-cultured against the autologous tumor cell line (1 x 10 5 effectors: 1 x 10 5 target cells) and reactivity was assessed by quantifying IFN-gamma release and the percentage of CD8 + cells expressing 4- IBB 24 hours after co-culture. The results are shown in Figure 6.
- PD-1 + sorted cells are more oligoclonal than PD- ⁇ cells after the numbers of cells are expanded in vitro.
- PD-1 + sorted cells include clones targeting mutated epitopes expressed by autologous tumor after the numbers of cells are expanded in vitro.
- a single cell suspension from a fresh melanoma tumor digest sample (FrTu#1913) was rested overnight without cytokines and sorted according to expression of PD-1 by FACS. The numbers of sorted cells were expanded in vitro for 14 days.
- TCR beta chain RNA was extracted using a ⁇ MACS RNA isolation kit (Miltenyi Biotec, Auburn, CA). cDNA synthesis and 5' RACE was carried out. Bar codes were introduced to the ends of the PCR product by PCR for identification of samples. The PCR product was washed and the library size was quantified. Deep sequencing was carried out (Illumina, Inc., San Diego, CA). The frequency of each unique TCR beta chain CDR3 region amino acid sequence in the population was determined. The results are shown in Figures 7A-7C. As shown in Figures 7A-7C, the PD-1 + sorted cells are more oligoclonal than PD- ⁇ cells after the numbers of cells are expanded in vitro.
- the 20 most frequent clonotypes in the PD-1 + population are shown in Figure 8.
- the most frequent TCR beta chain clonotypes in PD-1 + sorted cells after numbers of cells were expanded were found at a low frequency in the PD- ⁇ fraction.
- clones recognizing mutated epitopes that are expressed by autologous tumor cell line were found within the 20 most frequent clones in the PD-1 + population and at a very low frequency in the PD- ⁇ population.
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2902423A CA2902423C (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor-reactive t cells from tumor |
ES13722922T ES2859678T3 (en) | 2013-03-01 | 2013-04-30 | Methods for Producing Enriched Populations of Tumor-Reactive T Cells from a Tumor |
US14/771,615 US20160010058A1 (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor-reactive t cells from tumor |
JP2015560159A JP6416131B2 (en) | 2013-03-01 | 2013-04-30 | Method for producing an enriched tumor-reactive T cell population from a tumor |
CN201380075798.XA CN105163744A (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor-reactive T cells from tumor |
EP20217061.9A EP3821898A1 (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor-reactive t cells from tumor |
AU2013379772A AU2013379772B2 (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor-reactive T cells from tumor |
RU2015138483A RU2671897C2 (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumour-reactive t cells from tumour |
EP13722922.5A EP2961415B1 (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor-reactive t cells from tumor |
AU2018274874A AU2018274874B2 (en) | 2013-03-01 | 2018-12-04 | Methods of producing enriched populations of tumor reactive T cells from tumor |
AU2020220209A AU2020220209A1 (en) | 2013-03-01 | 2020-08-21 | Methods of producing enriched populations of tumor reactive T cells from tumor |
AU2022235535A AU2022235535A1 (en) | 2013-03-01 | 2022-09-20 | Methods of producing enriched populations of tumor reactive T cells from tumor |
US18/093,902 US20230265387A1 (en) | 2013-03-01 | 2023-01-06 | Methods of producing enriched populations of tumor-reactive t cells from tumor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361771247P | 2013-03-01 | 2013-03-01 | |
US61/771,247 | 2013-03-01 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/771,615 A-371-Of-International US20160010058A1 (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor-reactive t cells from tumor |
US18/093,902 Continuation US20230265387A1 (en) | 2013-03-01 | 2023-01-06 | Methods of producing enriched populations of tumor-reactive t cells from tumor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014133567A1 true WO2014133567A1 (en) | 2014-09-04 |
Family
ID=48444601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/038799 WO2014133567A1 (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor-reactive t cells from tumor |
Country Status (9)
Country | Link |
---|---|
US (2) | US20160010058A1 (en) |
EP (2) | EP2961415B1 (en) |
JP (4) | JP6416131B2 (en) |
CN (1) | CN105163744A (en) |
AU (4) | AU2013379772B2 (en) |
CA (1) | CA2902423C (en) |
ES (1) | ES2859678T3 (en) |
RU (1) | RU2671897C2 (en) |
WO (1) | WO2014133567A1 (en) |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
WO2016179006A1 (en) * | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
JP2017531640A (en) * | 2014-10-02 | 2017-10-26 | アメリカ合衆国 | Method for isolating a T cell receptor having antigen specificity for a cancer specific mutation |
JP2017535253A (en) * | 2014-10-02 | 2017-11-30 | アメリカ合衆国 | Method for isolating T cells having antigen specificity for a cancer specific mutation |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019027465A1 (en) | 2017-08-03 | 2019-02-07 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
EP3402512A4 (en) * | 2016-01-11 | 2019-09-25 | Armo Biosciences, Inc. | Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
JP2020019794A (en) * | 2019-10-02 | 2020-02-06 | アメリカ合衆国 | Methods for isolating t cells having antigen specificity to cancer specific mutations |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
US10760055B2 (en) | 2005-10-18 | 2020-09-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
JP2020143057A (en) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | Methods for isolating t cell receptors having antigen specificity to cancer specific mutations |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020191079A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
US10786534B2 (en) | 2013-03-11 | 2020-09-29 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US10835585B2 (en) | 2015-05-20 | 2020-11-17 | The Broad Institute, Inc. | Shared neoantigens |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
US10953048B2 (en) | 2012-07-20 | 2021-03-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2021173964A1 (en) * | 2020-02-28 | 2021-09-02 | KSQ Therapeutics, Inc. | Methods for activation and expansion of tumor infiltrating lymphocytes |
US11116796B2 (en) | 2016-12-02 | 2021-09-14 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
WO2021226085A1 (en) * | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
US11369678B2 (en) | 2008-08-28 | 2022-06-28 | Taiga Biotechnologies, Inc. | Compositions and methods for modulating immune cells |
US11401506B2 (en) | 2014-04-10 | 2022-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
JP2022130537A (en) * | 2019-10-02 | 2022-09-06 | アメリカ合衆国 | Methods of isolating t cells having antigenic specificity for cancer-specific mutation |
US11452768B2 (en) | 2013-12-20 | 2022-09-27 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US11667695B2 (en) | 2008-05-16 | 2023-06-06 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US11981922B2 (en) | 2020-10-05 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2961415B1 (en) * | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
CA3030156A1 (en) | 2016-07-07 | 2018-01-11 | Iovance Biotherapeutics, Inc. | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
WO2018057769A1 (en) | 2016-09-22 | 2018-03-29 | Corning Incorporated | Gravity flow cell culture devices, systems and methods of use thereof |
BR112019008305A2 (en) | 2016-10-26 | 2019-08-06 | Iovance Biotherapeutics Inc | methods for tumor infiltrating lymphocyte expansion, for assessing the metabolic activity of a tilde cell population, for treating a subject with cancer and for assaying for tils, and for expanded tile population |
TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
CA3044250A1 (en) | 2016-11-17 | 2018-05-24 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
KR20190104048A (en) | 2017-01-06 | 2019-09-05 | 이오반스 바이오테라퓨틱스, 인크. | Expansion of Tumor Infiltrating Lymphocytes (TIL) with Tumor Necrosis Factor Receptor Superfamily (TNFRSF) Agonists and Treatment Combinations of TILs and TNFRSF Agonists |
EP3565586A1 (en) | 2017-01-06 | 2019-11-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
JOP20190224A1 (en) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2018209115A1 (en) | 2017-05-10 | 2018-11-15 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2019103857A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
AR112072A1 (en) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | METHODS OF USE OF INFILTRATING TUMOR LYMPHOCYTES IN DOUBLE REFRACTORY MELANOMA |
SG11202004457XA (en) | 2017-11-17 | 2020-06-29 | Iovance Biotherapeutics Inc | Til expansion from fine needle aspirates and small biopsies |
JP2021508104A (en) | 2017-12-15 | 2021-02-25 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Systems and methods for determining beneficial administration of tumor-infiltrating lymphocytes and their use, as well as beneficial administration of tumor-infiltrating lymphocytes and their use. |
EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
CA3094957A1 (en) | 2018-03-29 | 2019-10-03 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
BR112020021660A2 (en) | 2018-04-27 | 2021-02-02 | Iovance Biotherapeutics, Inc. | methods for expanding tumor infiltrating lymphocytes and for treating an individual with cancer, tumor infiltrating lymphocyte population, and cryopreservation composition |
WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
TW202031273A (en) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | Treatment of nsclc patients refractory for anti-pd-1 antibody |
SG11202101787XA (en) | 2018-09-20 | 2021-04-29 | Iovance Biotherapeutics Inc | Expansion of tils from cryopreserved tumor samples |
BR112021008549A2 (en) | 2018-11-05 | 2022-01-04 | Iovance Biotherapeutics Inc | Method of treating non-small cell lung cancer with a population of tumor-infiltrating lymphocytes |
US20230039976A1 (en) | 2018-11-05 | 2023-02-09 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
US20220033775A1 (en) | 2018-11-05 | 2022-02-03 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathways inhibitors |
AU2019374761A1 (en) | 2018-11-05 | 2021-06-10 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
EP3898949A1 (en) | 2018-12-19 | 2021-10-27 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
CN110484504B (en) * | 2019-08-28 | 2022-10-14 | 复旦大学附属中山医院 | Cell subset for immunotherapy of primary hepatocellular carcinoma and preparation method thereof |
CA3155727A1 (en) | 2019-10-25 | 2021-04-29 | Cecile Chartier-Courtaud | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
US20210130438A1 (en) * | 2019-10-28 | 2021-05-06 | The Broad Institute, Inc. | Pan-cancer t cell exhaustion genes |
EP4073236A1 (en) | 2019-12-11 | 2022-10-19 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
EP4139440A1 (en) | 2020-04-22 | 2023-03-01 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
EP4146794A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
JP2023546359A (en) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
CA3201818A1 (en) | 2020-12-11 | 2022-06-16 | Maria Fardis | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
EP4263808A2 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
CA3205462A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
TW202242085A (en) | 2020-12-31 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
CA3212439A1 (en) | 2021-03-19 | 2022-09-22 | Michelle SIMPSON-ABELSON | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
IL306072A (en) | 2021-03-25 | 2023-11-01 | Iovance Biotherapeutics Inc | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
BR112023021665A2 (en) | 2021-04-19 | 2023-12-19 | Iovance Biotherapeutics Inc | METHOD FOR TREATING A CANCER, AND, COMPOSITION |
WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
CA3226942A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
CA3231018A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
CA3232700A1 (en) | 2021-09-24 | 2023-03-30 | Rafael CUBAS | Expansion processes and agents for tumor infiltrating lymphocytes |
CA3235824A1 (en) | 2021-10-27 | 2023-05-04 | Frederick G. Vogt | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
EP1432431B1 (en) | 2001-10-04 | 2017-05-10 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 activity |
PL2087904T3 (en) * | 2003-11-19 | 2014-01-31 | Survac Aps | Therapeutic use of peptides derived from Bcl-XL protein in cancer patients |
WO2007018198A1 (en) * | 2005-08-09 | 2007-02-15 | Kumamoto University | Cancer-rejection antigen peptide derived from hsp105 for use in hal-a2-positive patient and pharmaceutical comprising the antigen |
ES2363545B2 (en) * | 2010-01-26 | 2012-04-18 | Universidade De Santiago De Compostela | METHOD FOR IDENTIFYING AND PURIFYING HUMAN NATURAL REGULATOR T CELLS (NTREG). |
EP2961415B1 (en) * | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
-
2013
- 2013-04-30 EP EP13722922.5A patent/EP2961415B1/en active Active
- 2013-04-30 AU AU2013379772A patent/AU2013379772B2/en active Active
- 2013-04-30 CA CA2902423A patent/CA2902423C/en active Active
- 2013-04-30 RU RU2015138483A patent/RU2671897C2/en active
- 2013-04-30 ES ES13722922T patent/ES2859678T3/en active Active
- 2013-04-30 JP JP2015560159A patent/JP6416131B2/en active Active
- 2013-04-30 US US14/771,615 patent/US20160010058A1/en not_active Abandoned
- 2013-04-30 WO PCT/US2013/038799 patent/WO2014133567A1/en active Application Filing
- 2013-04-30 CN CN201380075798.XA patent/CN105163744A/en active Pending
- 2013-04-30 EP EP20217061.9A patent/EP3821898A1/en active Pending
-
2018
- 2018-04-26 JP JP2018085761A patent/JP6788629B2/en active Active
- 2018-12-04 AU AU2018274874A patent/AU2018274874B2/en active Active
-
2020
- 2020-08-21 AU AU2020220209A patent/AU2020220209A1/en not_active Abandoned
- 2020-10-30 JP JP2020182208A patent/JP7181917B2/en active Active
-
2022
- 2022-09-20 AU AU2022235535A patent/AU2022235535A1/en active Pending
- 2022-11-18 JP JP2022185113A patent/JP2023018043A/en active Pending
-
2023
- 2023-01-06 US US18/093,902 patent/US20230265387A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
Non-Patent Citations (3)
Title |
---|
GROS ALENA ET AL: "Selection of PD-1, LAG-3, TIM-3 and 41BB Positive CD8 T Cells in the Fresh Tumor Digest Enriches for Melanoma-Reactive Cells", JOURNAL OF IMMUNOTHERAPY; 27TH ANNUAL SCIENTIFIC MEETING OF THE SOCIETY-FOR-IMMUNOTHERAPY-OF-CANCER (SITC), LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US; NORTH BETHESDA, MD, USA, vol. 35, no. 9, 1 November 2012 (2012-11-01), pages 722 - 723, XP008165260, ISSN: 1524-9557, DOI: 10.1097/CJI.0B013E318272BDD9 * |
INOZUME TAKASHI ET AL: "Selection of CD8(+)PD-1(+) Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells", JOURNAL OF IMMUNOTHERAPY, vol. 33, no. 9, November 2010 (2010-11-01), pages 956 - 964, XP008165261, ISSN: 1524-9557 * |
PRIETO PETER A, DURFLINGER KATHERINE H, WUNDERLICH JOHN R, ROSENBERG STEVEN A, DUDLEY MARK E: "Enrichment of CD8(+) Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy", JOURNAL OF IMMUNOTHERAPY, vol. 33, no. 5, June 2010 (2010-06-01), pages 547 - 556, XP008165262, ISSN: 1524-9557, DOI: 10.1097/CJI.0b013e3181d367bd * |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10760055B2 (en) | 2005-10-18 | 2020-09-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
US11667695B2 (en) | 2008-05-16 | 2023-06-06 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
US11369678B2 (en) | 2008-08-28 | 2022-06-28 | Taiga Biotechnologies, Inc. | Compositions and methods for modulating immune cells |
US10953048B2 (en) | 2012-07-20 | 2021-03-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US10786534B2 (en) | 2013-03-11 | 2020-09-29 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11834718B2 (en) | 2013-11-25 | 2023-12-05 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
US11452768B2 (en) | 2013-12-20 | 2022-09-27 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
US11401506B2 (en) | 2014-04-10 | 2022-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
JP2017531640A (en) * | 2014-10-02 | 2017-10-26 | アメリカ合衆国 | Method for isolating a T cell receptor having antigen specificity for a cancer specific mutation |
JP2017535253A (en) * | 2014-10-02 | 2017-11-30 | アメリカ合衆国 | Method for isolating T cells having antigen specificity for a cancer specific mutation |
US10973894B2 (en) | 2014-10-02 | 2021-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
US11939637B2 (en) | 2014-12-19 | 2024-03-26 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
US11629334B2 (en) | 2015-05-01 | 2023-04-18 | The United States of Americans represented by the Secretary, Department of Health and Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
US10544392B2 (en) | 2015-05-01 | 2020-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
AU2016258845B2 (en) * | 2015-05-01 | 2022-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
WO2016179006A1 (en) * | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
US10835585B2 (en) | 2015-05-20 | 2020-11-17 | The Broad Institute, Inc. | Shared neoantigens |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
US11180730B2 (en) | 2015-10-28 | 2021-11-23 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 |
US11186825B2 (en) | 2015-10-28 | 2021-11-30 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
US11884717B2 (en) | 2015-11-19 | 2024-01-30 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
EP3402512A4 (en) * | 2016-01-11 | 2019-09-25 | Armo Biosciences, Inc. | Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
US11116796B2 (en) | 2016-12-02 | 2021-09-14 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019027465A1 (en) | 2017-08-03 | 2019-02-07 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US10864259B2 (en) | 2017-08-03 | 2020-12-15 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
EP4026554A1 (en) | 2017-08-03 | 2022-07-13 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020191079A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
JP2021119175A (en) * | 2019-10-02 | 2021-08-12 | アメリカ合衆国 | Methods for isolating t cells having antigenic specificity for cancer specific mutations |
JP2020019794A (en) * | 2019-10-02 | 2020-02-06 | アメリカ合衆国 | Methods for isolating t cells having antigen specificity to cancer specific mutations |
JP7340144B2 (en) | 2019-10-02 | 2023-09-07 | アメリカ合衆国 | Method for isolating T cells with antigenic specificity for cancer-specific mutations |
JP2022130537A (en) * | 2019-10-02 | 2022-09-06 | アメリカ合衆国 | Methods of isolating t cells having antigenic specificity for cancer-specific mutation |
JP7096397B2 (en) | 2019-10-02 | 2022-07-05 | アメリカ合衆国 | Methods for Isolating T Cells with Antigen Specificity to Cancer-Specific Mutations |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
WO2021173964A1 (en) * | 2020-02-28 | 2021-09-02 | KSQ Therapeutics, Inc. | Methods for activation and expansion of tumor infiltrating lymphocytes |
JP7437444B2 (en) | 2020-04-01 | 2024-02-22 | アメリカ合衆国 | Method for isolating T cell receptors with antigenic specificity for cancer-specific mutations |
JP2020143057A (en) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | Methods for isolating t cell receptors having antigen specificity to cancer specific mutations |
JP2022106957A (en) * | 2020-04-01 | 2022-07-20 | アメリカ合衆国 | Methods for isolating t cell receptors having antigen specificity to cancer specific mutations |
WO2021226085A1 (en) * | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
US11981922B2 (en) | 2020-10-05 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
Also Published As
Publication number | Publication date |
---|---|
EP3821898A1 (en) | 2021-05-19 |
RU2018136226A (en) | 2019-03-21 |
EP2961415B1 (en) | 2021-01-06 |
JP2016509839A (en) | 2016-04-04 |
RU2671897C2 (en) | 2018-11-07 |
JP6788629B2 (en) | 2020-11-25 |
AU2022235535A1 (en) | 2022-10-13 |
ES2859678T3 (en) | 2021-10-04 |
AU2013379772B2 (en) | 2018-09-20 |
JP2021019634A (en) | 2021-02-18 |
CA2902423C (en) | 2021-06-29 |
JP2018148898A (en) | 2018-09-27 |
AU2013379772A1 (en) | 2015-09-17 |
US20160010058A1 (en) | 2016-01-14 |
CA2902423A1 (en) | 2014-09-04 |
JP6416131B2 (en) | 2018-10-31 |
US20230265387A1 (en) | 2023-08-24 |
JP2023018043A (en) | 2023-02-07 |
JP7181917B2 (en) | 2022-12-01 |
EP2961415A1 (en) | 2016-01-06 |
AU2018274874A1 (en) | 2019-02-28 |
AU2018274874B2 (en) | 2020-05-21 |
RU2015138483A (en) | 2017-04-13 |
CN105163744A (en) | 2015-12-16 |
AU2020220209A1 (en) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230265387A1 (en) | Methods of producing enriched populations of tumor-reactive t cells from tumor | |
US11679128B2 (en) | Methods of producing enriched populations of tumor reactive T cells from peripheral blood | |
RU2808817C2 (en) | Methods for producing enriched populations of tumor-reactive t-cells from a tumor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201380075798.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13722922 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2902423 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14771615 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015560159 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013379772 Country of ref document: AU Date of ref document: 20130430 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013722922 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015138483 Country of ref document: RU Kind code of ref document: A |